Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Tehran University of Medical Sciences80 enrolled

Overview

Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

simvastatinDRUG

40 mg/ day

placeboDRUG

80 mg /day

Eligibility

Sex: ALLMin age: 15 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. edss\<5 2. \>=1 attack in last year Exclusion Criteria: 1. \>2 attacks in study 2. drug complication

Locations (1)

Sanaz Ahmadi

Tehran, Iran

Outcomes

Primary Outcomes

attack number

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.